<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05094544</url>
  </required_header>
  <id_info>
    <org_study_id>IIT-2020-POIMS-Lung</org_study_id>
    <nct_id>NCT05094544</nct_id>
  </id_info>
  <brief_title>Pre-Operative Immuno-Modulatory SBRT (POIMS Trial): A Pilot Trial in Early Stage NSCLC</brief_title>
  <acronym>POIMS</acronym>
  <official_title>Pre-Operative Immuno-Modulatory SBRT (POIMS Trial): A Pilot Trial in Early Stage NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current proposal is structured as a pilot trial to evaluate the impact of non-ablative&#xD;
      SBRT (800 cGy X 3 fractions) as an immunomodulatory mechanism in patients with early stage&#xD;
      NSCLC who are surgical candidates. Tumor, normal tissue and blood specimens will be analyzed&#xD;
      for immunomodulatory changes including phenotypic changes in tumor cell surface marker&#xD;
      expression, tumor and normal tissue microenvironment and gene expression profiles,&#xD;
      serum/blood immune profile changes, and circulating tumor cell immunophenotypic and gene&#xD;
      expression alterations.&#xD;
&#xD;
      Published literature showed that cytotoxic doses of XRT may not elicit a clinically&#xD;
      meaningful alteration in the immune profile. Further, studies using an animal model have&#xD;
      concluded a fractionated regimen induces a greater abscopal effect than single dose&#xD;
      radiation. Furthermore, research has shown a regimen of 800 cGy X 3 fractions yielded the&#xD;
      most significant changes in the immune profile compared to 2000 cGy X 1 or 600 cGy X 5.&#xD;
&#xD;
      The immune response within the tumor milieu is a complex dynamic process with an interplay&#xD;
      among lymphocyte subsets, antigen presenting cells/dendritic cells, macrophages, and tumor&#xD;
      cells. The interactions between the various components is orchestrated by a variety of&#xD;
      extracellular and intracellular signaling pathways involving ligand and cell surface&#xD;
      expression, cytokine release, and activation or inhibition of a variety of T cell subsets. In&#xD;
      order to comprehensively define the immunomodulatory effect of three fractions of 800 cGy on&#xD;
      the primary tumor, the investigators will analyze the following: tumor cell surface&#xD;
      phenotype, tumor microenvironment immune profile and gene expression profile, T cell&#xD;
      repertoire changes in tumor tissue and peripheral blood, and circulating tumor cell phenotype&#xD;
      and gene expression profiles. Each of these components has been shown to be impacted by&#xD;
      radiation in either a cell culture or animal model systems. By characterizing, quantitating&#xD;
      and defining these changes related to three fractions of 800 cGy, it will directly provide&#xD;
      important insights to inform rational uses of XRT and immunotherapy in the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">April 2026</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in tumor T cell repertoire following pre and post SBRT</measure>
    <time_frame>through study completion, an average of 18 months</time_frame>
    <description>Pre and post study intervention biopsy tissue comparison</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The impact of pre-surgical non-ablative SBRT on peri- and post-operative surgical complication rate</measure>
    <time_frame>From Day of post-SBRT surgery through 6 month (± 2 months) post-operative follow up visit</time_frame>
    <description>Medical Record Review Clavien-Dindo Classification system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of SBRT on post-surgical wound healing complication rate assessed by CTCAE v5</measure>
    <time_frame>From Day of post-SBRT surgery through 6 month (± 2 months) post-operative follow up visit</time_frame>
    <description>Medical record review General Thoracic Surgery Database.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional control disease</measure>
    <time_frame>From Day of enrollment through 36 month follow up visit</time_frame>
    <description>Medical record review&#xD;
Loco-regional metastasisi</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis-free survival</measure>
    <time_frame>From Day of enrollment through 36 month follow up visit</time_frame>
    <description>Medical record review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From Day of enrollment through 36 month follow up visit</time_frame>
    <description>Medical record review</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Non-ablative SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-ablative SBRT (800 cGy X 3 fractions) given 5-7 days preoperatively in selected patients with stage I-II NSCLC</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Non-ablative SBRT</intervention_name>
    <description>Non-ablative SBRT (800 cGy X 3 fractions) given 5-7 days preoperatively in selected patients with stage I-II NSCLC</description>
    <arm_group_label>Non-ablative SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stage I-II NSCLC&#xD;
&#xD;
          -  Adequate diagnostic biopsy tissue to allow pre-SBRT tumor analysis&#xD;
&#xD;
          -  Candidate for oncologic surgery (lobectomy or sub lobar resection) for the lung cancer&#xD;
&#xD;
          -  Lesion located peripherally, ≥ 2 cm from bronchial margin, and 1 cm from visceral&#xD;
             pleura, with location deemed acceptable by cardio-thoracic surgeon for resection.&#xD;
&#xD;
          -  Adequate pulmonary function test results&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of lung/chest wall surgery&#xD;
&#xD;
          -  Prior chest radiation&#xD;
&#xD;
          -  Prior immunotherapy&#xD;
&#xD;
          -  History of autoimmune disease&#xD;
&#xD;
          -  Currently using immunosuppressive drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shalina Gupta-Burt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shalina Gupta-Burt, MD</last_name>
    <phone>913-588-3600</phone>
    <email>sguptaburt@kumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rhyan Kubik</last_name>
    <phone>913-588-3610</phone>
    <email>rkubik@kumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Schroeder, MPH</last_name>
      <phone>913-588-3600</phone>
      <email>aschroeder3@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Shalina Gupta-Burt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Shalina Gupta-Burt</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>SBRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT05094544/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 1, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT05094544/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

